• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Yogen Saunthararajah, MD

Professor of Medicine
Cleveland Clinic Main Campus
9500 Euclid Avenue
Cleveland, Ohio, United States

Yogen Saunthararajah, MD, is a staff in the department of Hematologic Oncology and Blood Disorders at Cleveland Clinic, a professor of medicine, and co-leader of the developmental therapeutics program of the Case Comprehensive Cancer Center.

His clinical and research interests include acute myeloid leukemia, myelodysplastic syndrome, sickle cell disease/anemia, thalassemia, leukemia, benign hematology, myelodysplasia, cancer, leukopenia, aplastic anemia.

Dr. Yogen developed an Epigenetic Platform that has the potential to identify and eliminate the “road blocks” that prevent cancer cells from becoming specialized, non-dividing cells. According to him, the methodology can be applied to some of the most common and most debilitating genetic disorders in the world, including sickle cell disease and beta thalassemia.

expertly curated content related to this topic

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.